-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes
-- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutations
Read more at globenewswire.com